Oxford BioDynamics Plc
OBD.L · LSE
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | -0.56 | 0.25 |
| FCF Yield | -117.26% | -130.76% | -16.51% | -53.01% |
| EV / EBITDA | -1.05 | -1.18 | -5.67 | -2.70 |
| Quality | ||||
| ROIC | -153.84% | -107.20% | -76.01% | -77.00% |
| Gross Margin | -561.55% | 45.44% | 52.16% | 75.32% |
| Cash Conversion Ratio | 0.69 | 0.85 | 0.77 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.01% | 60.44% | 14.36% | -30.36% |
| Free Cash Flow Growth | 28.24% | -19.50% | -48.24% | 32.52% |
| Safety | ||||
| Net Debt / EBITDA | -0.38 | -0.38 | -0.12 | -0.84 |
| Interest Coverage | -25.27 | -57.31 | -51.77 | -44.11 |
| Efficiency | ||||
| Inventory Turnover | 37.15 | 1.08 | 0.89 | 0.11 |
| Cash Conversion Cycle | 174.75 | 130.07 | 860.24 | -1,607.82 |